Catalyst Wire Dossier Catalyst Wire Dossier

lulizumab

BMS-931699 · Bristol-Myers Squibb
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for lulizumab, covering 2018-10-04 to 2018-10-04. Get the full timeline:

Most recent: Clinical Trial Update: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome [Phase 2]

See pricing